Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results from the phase 3 DELTA-1 and-2 studies

被引：0
|
作者：
Bissonnette, R. [1 ]
Worm, M. [2 ]
Warren, R. B. [3 ,4 ]
Agner, T. [5 ]
Gooderham, M. [6 ,7 ]
Schuttelaar, M. L. [8 ]
Baranowski, K. [9 ]
Plohberger, U. [9 ]
Soerensen, L. [9 ]
Schliemann, S. [10 ]
机构：
[1] Innovaderm Res, Montreal, PQ, Canada
[2] Charite, Klin Allergie Immunol, Klin Dermatol & Venerol Allergie, Berlin, Germany
[3] Northern Care Alliance NHS Fdn Trust, Dermatol Zentrum, Manchester, England
[4] Manchester Univ NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester, England
[5] Univ Kopenhagen, Bispebjerg Krankenhaus, Abt Dermatol, Copenhagen, Denmark
[6] Queens Univ, Peterborough, ON, Canada
[7] SKiN Zentrum Dermatol Med Forsch, Peterborough, ON, Canada
[8] Univ Groningen, Univ klinikum Groningen, Groningen, Netherlands
[9] LEO Pharm A S, Ballerup, Denmark
[10] Univ Klinikum Jena, Klin Dermatol, Jena, Germany
来源：
ALLERGOLOGIE | 2024年 / 47卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：55
相关论文
共 50 条
  • [1] Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the phase 3 DELTA-1 and-2 trials
    Bissonnette, Robert
    Worm, Margitta
    Warren, Richard B.
    Agner, Tove
    Gooderham, Melinda
    Schuttelaar, Marie Louise
    Baranowski, Keith
    Plohberger, Ursula
    Soerensen, Laura
    Schliemann, Sibylle
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [2] Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and-2 trials
    Bauer, Andrea
    Schuttelaar, Marie-Louise
    Baranowski, Keith
    Plohberger, Ursula
    Sorensen, Laura
    Worm, Margitta
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [3] Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, trials
    Bissonnette, Robert
    Warren, Richard B.
    Pinter, Andreas
    Agner, Tove
    Gooderham, Melinda
    Schuttelaar, Marie L. A.
    Crepy, Marie-Noelle
    Stingeni, Luca
    Serra-Baldrich, Esther
    Baranowski, Keith
    Korn, Sofie
    Kurvits, Merle
    Plohberger, Ursula
    Vest, Natacha Strange
    Schliemann, Sibylle
    LANCET, 2024, 404 (10451): : 461 - 473
  • [4] Systemic exposure and safety profile of delgocitinib cream in adults with moderate to severe chronic hand eczema in the phase 3 DELTA-2 trial
    Gooderham, Melinda
    Thaci, Diamant
    Damgaard, Tina
    Madsen, Daniel
    Soehoel, Anders
    Bissonnette, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [5] Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial
    Gooderham, Melinda
    Molin, Sonja
    Bissonnette, Robert
    Worm, Margitta
    Crepy, Marie-Noelle
    Stingeni, Luca
    Warren, Richard B.
    Schliemann, Sibylle
    Balita-Crisostomo, Cherry Lou
    Oesterdal, Marie Louise
    Agner, Tove
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 35 - 36
  • [6] A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the Hand Eczema Severity Index (HECSI)
    Soerensen, Per
    Soerensen, Per
    Griffiths, Philip
    Nielsen, Thor Schuett Svane
    Larsen, Lotte Seiding
    Resen, Katarina
    Agner, Tove
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB121 - AB121
  • [7] Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial
    Bauer, Andrea
    Thyssen, Jacob P. P.
    Buhl, Timo
    Nielsen, Thor Schutt Svane
    Larsen, Lotte Seiding
    Osterskov, Anne Birk
    Agner, Tove
    CONTACT DERMATITIS, 2023, 89 (01) : 46 - 53
  • [8] THE IMPACT OF MODERATE TO SEVERE CHRONIC HAND ECZEMA AND THE EFFECT OF IMPROVED CLINICAL SYMPTOMS ON WORK PRODUCTIVITY LOSS: DATA FROM THE DELTA 1 AND DELTA 2 PHASE 3 TRIALS
    Bauer, A.
    Halling, C.
    Korn, S.
    Nyholm, N.
    VALUE IN HEALTH, 2023, 26 (12) : S456 - S456
  • [9] Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: Pooled Results from two phase 3 studies
    Eichenfield, Lawrence F.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB158 - AB158
  • [10] Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study
    Worm, M.
    Bauer, A.
    Elsner, P.
    Mahler, V.
    Molin, S.
    Nielsen, T. S. S.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (05) : 1103 - 1110
12345